Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy.
Lutz R, Grünschläger F, Simon M, Awwad MHS, Bauer M, Yousefian S, Beumer N, Jopp-Saile L, Sedlmeier A, Solé-Boldo L, Avanesyan B, Vonficht D, Stelmach P, Steinbuss G, Boch T, Steiger S, Baertsch MA, Prokoph N, Rippe K, Durie BGM, Wickenhauser C, Trumpp A, Müller-Tidow C, Hübschmann D, Weinhold N, Raab MS, Brors B, Goldschmidt H, Imbusch CD, Hundemer M, Haas S. Lutz R, et al. Among authors: muller tidow c. Nat Commun. 2024 Nov 29;15(1):10396. doi: 10.1038/s41467-024-54543-0. Nat Commun. 2024. PMID: 39613747 Free PMC article.
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype.
Leppä AM, Grimes K, Jeong H, Huang FY, Andrades A, Waclawiczek A, Boch T, Jauch A, Renders S, Stelmach P, Müller-Tidow C, Karpova D, Sohn M, Grünschläger F, Hasenfeld P, Benito Garagorri E, Thiel V, Dolnik A, Rodriguez-Martin B, Bullinger L, Mrózek K, Eisfeld AK, Krämer A, Sanders AD, Korbel JO, Trumpp A. Leppä AM, et al. Among authors: muller tidow c. Nat Genet. 2024 Nov 25. doi: 10.1038/s41588-024-01999-x. Online ahead of print. Nat Genet. 2024. PMID: 39587361
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Récher C, Dumas PY, Bérard E, Tavitian S, Leguay T, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Luquet I, Klein E, de Grande AC, Sarry A, Zukunft S, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M, Serve H, Bertoli S, Pigneux A, Röllig C. Récher C, et al. Among authors: muller tidow c. Am J Hematol. 2024 Nov 18. doi: 10.1002/ajh.27510. Online ahead of print. Am J Hematol. 2024. PMID: 39555737
Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia.
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Ruhnke L, et al. Among authors: muller tidow c. Blood Adv. 2024 Nov 6:bloodadvances.2024013304. doi: 10.1182/bloodadvances.2024013304. Online ahead of print. Blood Adv. 2024. PMID: 39504561
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Among authors: muller tidow c. Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14304. Online ahead of print. Eur J Haematol. 2024. PMID: 39400388
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.
Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, Friedrich MJ, Michel CS, Hajiyianni M, Breitkreutz I, Costello P, Nadeem O, Weinhold N, Goldschmidt H, Schmitt A, Luft T, Schmitt M, Müller-Tidow C, Topp M, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. Frenking JH, et al. Among authors: muller tidow c. J Immunother Cancer. 2024 Oct 7;12(10):e009220. doi: 10.1136/jitc-2024-009220. J Immunother Cancer. 2024. PMID: 39379098 Free PMC article.
Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
Unglaub JM, Schlenk RF, Middeke JM, Krause SW, Kraus S, Einsele H, Kramer M, Zukunft S, Kauer J, Renders S, Katelari E, Schliemann C, Pabst C, Luft T, Dreger P, Röllig C, Bornhäuser M, Müller-Tidow C, Sauer T. Unglaub JM, et al. Among authors: muller tidow c. Blood Adv. 2024 Sep 18:bloodadvances.2024013086. doi: 10.1182/bloodadvances.2024013086. Online ahead of print. Blood Adv. 2024. PMID: 39293081
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, Neuber B, Schmitt A, Raffel S, Liu Y, Janssen M, Müller-Tidow C, Schmitt M, Sauer T. Sedloev D, et al. Among authors: muller tidow c. J Hematol Oncol. 2024 Sep 16;17(1):85. doi: 10.1186/s13045-024-01604-y. J Hematol Oncol. 2024. PMID: 39285441 Free PMC article.
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M. Röllig C, et al. Among authors: muller tidow c. J Clin Oncol. 2024 Sep 16:JCO2400235. doi: 10.1200/JCO.24.00235. Online ahead of print. J Clin Oncol. 2024. PMID: 39284116
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, Röthemeier C, Neuber B, Hückelhoven-Krauss A, Brüggemann M, Bernhard H, Kobbe G, Lindemann A, Rummel M, Michels B, Korell F, Ho AD, Müller-Tidow C, Schmitt M. Derigs P, et al. Among authors: muller tidow c. Leukemia. 2024 Nov;38(11):2419-2428. doi: 10.1038/s41375-024-02392-7. Epub 2024 Aug 27. Leukemia. 2024. PMID: 39192036 Free PMC article. Clinical Trial.
521 results